Regenxbio Inc (NASDAQ: RGNX) on Monday, plunged -3.55% from the previous trading day, before settling in for the closing price of $8.74. Within the past 52 weeks, RGNX’s price has moved between $5.03 and $15.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -12.18% annually for the last half of the decade. The company achieved an average annual earnings per share of 93.72%. With a float of $45.66 million, this company’s outstanding shares have now reached $50.12 million.
In an organization with 353 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 76.54%, operating margin of -100.41%, and the pretax margin is -100.62%.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regenxbio Inc is 9.38%, while institutional ownership is 86.64%. The most recent insider transaction that took place on May 12 ’25, was worth 163,046. In this transaction Director of this company sold 20,602 shares at a rate of $7.91, taking the stock ownership to the 475,103 shares. Before that another transaction happened on May 12 ’25, when Company’s Director proposed sale 20,602 for $7.52, making the entire transaction worth $154,927.
Regenxbio Inc (RGNX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 93.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.05% during the next five years compared to -12.18% drop over the previous five years of trading.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Regenxbio Inc (RGNX) is currently performing well based on its current performance indicators. A quick ratio of 2.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.14, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -1.51 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.67 million. That was inferior than the volume of 1.05 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.38%.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 56.92%, which indicates a significant increase from 40.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.33% in the past 14 days, which was lower than the 100.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.99, while its 200-day Moving Average is $8.58. However, in the short run, Regenxbio Inc’s stock first resistance to watch stands at $8.68. Second resistance stands at $8.93. The third major resistance level sits at $9.07. If the price goes on to break the first support level at $8.29, it is likely to go to the next support level at $8.14. The third support level lies at $7.89 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
Market capitalization of the company is 424.78 million based on 50,160K outstanding shares. Right now, sales total 83,330 K and income totals -227,100 K. The company made 89,010 K in profit during its latest quarter, and 6,080 K in sales during its previous quarter.
